Graves Ophthalmopathy
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Graves ophthalmopathy is an emerging landscape with 19 programs across 13 companies. The most active players are Vitae Pharmaceuticals Inc., an Allergan affiliate, Amphastar Pharmaceuticals, Inc., Regeneron. 11 therapies are approved with 2 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Analysis
Modality Breakdown
70%
Small molecule
14 of 20 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 20 classified programs, each share of the total. Modality classified for 100% of 20 pipeline programs.
Analysis
Trial Status
1
clinical trials
Clinical Trials
Trial Activity
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)